Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths among men in most Western countries. Despite its high morbidity and mortality, the etiology of prostate cancer remains obscure. Although compelling laboratory data suggest a role for androgens in prostate carcinogenesis, most epidemiologic data, including serological and genetic studies, are inconclusive. In this chapter, we review the status of serologic studies and discuss the importance of intra-prostatic hormone levels in possibly clarifying the often-contradictory data on serologic studies. To provide insights and directions for epidemiologic research on hormones and prostate cancer, this review centers on the molecular epidemiology of hormone-related genetic loci. These loci have been investigated in a number of studies to date and will undoubtedly expand even further as rich new genetic information sources and highthroughput genotyping and analysis methods become
ABSTRACT
Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths among men in most Western countries. Despite its high morbidity and mortality, the etiology of prostate cancer remains obscure. Although compelling laboratory data suggest a role for androgens in prostate carcinogenesis, most epidemiologic data, including serological and genetic studies, are inconclusive. In this chapter, we review the status of serologic studies and discuss the importance of intra-prostatic hormone levels in possibly clarifying the often-contradictory data on serologic studies. To provide insights and directions for epidemiologic research on hormones and prostate cancer, this review centers on the molecular epidemiology of hormone-related genetic loci. These loci have been investigated in a number of studies to date and will undoubtedly expand even further as rich new genetic information sources and highthroughput genotyping and analysis methods become available. Due to the enormous number of these loci, we recommend careful analysis and cautious interpretation of studies of genetic markers, including microsatellites and single nucleotide polymorphisms (SNPs), as false positive and negative results are likely due to limited statistical power, multiple hypothesis testing, population stratification, or non-representative population sampling. This review also highlights the need for replication in various populations, as well as reasons for performing functional analyses of SNPs, a critical and often underappreciated component of molecular epidemiologic investigations. The time is ripe for concerted, large-scale multidisciplinary investigations that incorporate molecular genetics, biochemistry, histopathology, and endocrinology into traditional epidemiologic studies. Such collaboration will lead to a deeper understanding of the etiologic pathways of prostate cancer, ultimately yielding better preventive, diagnostic, and therapeutic strategies.
INTRODUCTION
Prostate cancer is the most common non-skin cancer among American men, with 234,460 new cases expected in 2006, and it ranks third in number of estimated male cancer deaths (n=27,350), behind only lung and colorectal cancer (1) . Despite the magnitude of prostate cancer incidence and mortality, few risk factors have been identified other than age, race, and family history.
Prostate cancer is a hormone-mediated cancer. Abundant biological data have shown that the growth and maintenance of the prostate are dependent on androgens, that prostate cancer regresses after androgen ablation or anti-androgen therapy, and that administration of testosterone induces prostate tumors in laboratory animals (2) (3) (4) . Estrogen compounds have long been used to control prostate cancer growth, though recognition of their serious cardiac and sexual side effects have diminished their use (5) . Similarly, strong laboratory evidence shows that vitamin D, another steroid hormone, has strong antiproliferative and pro-apoptotic effects on prostate cancer (6) . In addition, obesity, which has been linked to elevated risk of aggressive prostate cancer and prostate cancer death (7) , is associated with lower levels of sex hormone-binding globulin (SHBG) and presumably higher levels of free testosterone (8) . However, despite numerous studies of both prospective and retrospective designs, there has been no convincing epidemiological evidence linking circulating levels of these hormones to prostate cancer risk (6, 9) . A number of methodological issues, discussed below, have been suggested to explain these inconsistencies.
Family history is an established risk factor for prostate cancer: men with a first-degree affected relative (father, brother) have a 2-3-fold increased risk (10) , and it has been estimated that 42% (95% CI 29-50%) of prostate cancer risk is explained by genetic factors, the highest for any human cancer (11) . More recent epidemiological investigations have attempted to exploit this known heritability by focusing on hormone-related genes as a path to understanding the role of hormones in prostate cancer. However, though these studies provide exciting new evidence and leads regarding the specific roles played by hormones and hormone-related genetic loci, results to date have not been conclusive. Indeed, despite the large number of publications resulting from the sudden wealth of genetic data enabled by recent genotyping technology advances, few of the reported findings have been replicated (12) , and this trend is likely to continue as the technologies improve further. It is possible that the familial and sporadic forms of the disease are etiologically distinct.
This review summarizes current perspectives on steroid hormone metabolism, epidemiologic data on androgenic and non-androgenic hormones in prostate cancer, and polymorphisms of genes involved in androgen metabolism and regulation. Through this effort, we attempt to provide insights and directions for future research on hormone-related genetic loci and prostate cancer.
ANDROGENS

Biosynthesis and Metabolism of Androgens
Androgens are steroid hormones that induce the differentiation and maturation of the male reproductive organs and the development of male secondary sex characteristics. In men, androgens are formed primarily in the testes and the adrenal gland, and to a lesser extent in peripheral tissues, such as the prostate and skin. Formation of androgens in the endocrine glands occurs by well-characterized biosynthetic pathways ( Figure 1 ).
Testosterone is the principal androgen in circulation, while dihydrotestosterone (DHT) is the primary nuclear androgen and the most potent androgen. In the circulation of adult males, roughly 44% of testosterone is bound with high affinity to SHBG, 54% is bound with low affinity to albumin, and only 1-2% of testosterone exists in a free (unbound) state. About 25% of the DHT in the circulation is secreted by the testes, while most (65-75%) arises from conversion of testosterone in peripheral tissue in a reaction catalyzed by the enzyme steroid 5 alpha-reductase or from circulating inactive androgens, such as androstenedione, dehydroepiandrosterone (DHEA), and DHEA sulfate (DHEAS). In humans, two steroid 5 alpha-reductase isoenzymes have been identified. The type 1 enzyme (encoded by the SRD5A1 gene) is expressed mostly in skin and hair, whereas the type 2 enzyme (encoded by the SRD5A2 gene) is localized primarily in androgen target tissue, including genital skin and the prostate (13) .
In men, the prostate is a major site of nontesticular DHT production from testosterone. Free testosterone in circulation enters prostate cells by passive diffusion, whereas albumin-bound testosterone, because of its low affinity for albumin, can disassociate from albumin, allowing it to enter prostatic cells. In addition, recent evidence of SHBG receptors on the surface of prostate cells suggests that SHBG-bound testosterone may also enter prostate cells (14, 15) . Figure 2 shows the metabolic pathways of androgens within the prostate gland. The concentration of DHT in serum is a fraction of that of testosterone (16) , whereas the concentration of DHT in prostatic tissue is several times higher than that of testosterone, suggesting that DHT levels in tissue are important in prostate development and tumorigenesis. However, tissue levels of testosterone and DHT are difficult to measure in epidemiologic studies, and thus, the serum concentration of 3 alpha-diol G (3 alpha androstanediol glucuronide; AAG) is commonly used as an indirect measure of steroid 5alpha-reductase enzymatic activity or, more generally, of intra-prostatic androgenicity. The concentration of 3alpha-diol G in serum correlates well with steroid 5alpha-reductase activity in genital skin (17, 18) . Although serum levels of 3alpha-diol G may reflect enzyme activities of both the type 1 and type 2 steroid 5alpha-reductase enzymes, recent data from studies of finasteride, a type 2 steroid 5alpha-reductase inhibitor, show that serum levels of DHT and 3alpha-diol G decrease concomitantly in treated men, suggesting that serum levels of 3alpha-diol G may predominantly reflect the activity of the type 2 steroid 5alpha-reductase (19).
Androgen Action on the Prostate
The action of DHT in the prostate is mediated by the androgen receptor (AR) (Figure 2 ). Within the prostate, DHT binds to the AR to form an intracellular complex which binds to androgen-response elements in the DNA of prostate cells, ultimately inducing proliferation. Though the tissue concentration of DHT necessary to initiate the androgen cascade is unknown, just a minute amount is required to trigger androgenic action in prostate cancer patients who have undergone androgen ablation treatment, perhaps because such patients have hypersensitive ARs (20, 21) . In the absence of androgen, non-androgenic hormones including estradiol, vitamin D, and insulin-like growth factors (IGFs) can bind ARs, triggering androgenic action (22, 23) . In addition, the activity of the AR is modulated by a series of coactivator proteins, including ARA54, ARA55, ARA70, ARA160, p160, BRCA1, AIB1, and CBP, which can enhance AR transcriptional activity several-fold (24) (25) (26) . Thus, androgenic action within the prostate is determined not only by androgen concentration but also by numerous other factors, including factors yet to be identified. However, no epidemiologic studies have directly assessed tissue hormone levels or androgenic action within the prostate, due in part to the difficulty in collecting prostate tissue from control subjects in casecontrol studies, or from men at baseline in cohort studies.
Androgens and Prostate Cancer: Epidemiologic Evidence
Most epidemiologic studies have compared serum levels of androgens in prostate cancer cases with those in healthy subjects in either case-control or prospective studies. In case-control studies, blood samples from cancer patients are collected after diagnosis (usually before treatment) and assayed for hormone levels. Thus, the presence of disease may have an effect on circulating levels of hormone. Moreover, these types of crosssectional studies make it difficult to establish a temporal relationship between androgens and prostate cancer. In contrast, prospective studies, such as nested case-control studies, compare serum levels of hormones in prediagnostic blood samples from incident cases identified in a prospective follow-up to those of healthy controls selected from the same cohort. Because blood samples of the case subjects are usually collected several years before the diagnosis of cancer, potential effects of disease on the measurement of hormones are presumably minimized.
Several prospective studies have evaluated the role of serum hormones in prostate cancer. Although two studies reported a statistically significant association between serum levels of testosterone and prostate cancer (16, 27) , several found suggestive, but statistically nonsignificant, associations between prostate cancer and serum levels of testosterone and DHT (28, 29) . Recent studies have shown elevated risk of low-grade prostate cancer and reduced risk of high-grade prostate cancer to be associated with higher levels of serum testosterone (30, 31) . This might explain, in part, inconsistent results of studies linking obesity to both increased risk of aggressive prostate cancer and decreased risk of overall and low-grade tumors (7), as obesity is associated with lower serum levels of androgens (8) . Earlier studies using the ratio of serum testosterone to DHT as an indirect measure of steroid 5alpha-reductase type 2 activity, suggested a role for the steroid 5alpha-reductase type 2 enzyme (28, 29). However, more recent studies have found no significant association between prostate cancer risk and serum levels of 3alpha-diol G, a surrogate marker for steroid 5alpha-reductase activity within the prostate (16, (31) (32) (33) (34) (35) (36) (37) .
In most of these studies, the failure to show an association between androgen levels and prostate cancer risk may be due, in part, to methodologic limitations that include difficulty in making reliable measurements of circulating hormone levels in an epidemiologic setting. It is possible that free, unbound testosterone is more etiologically relevant than total testosterone, but because it is infeasible to directly measure free testosterone in epidemiological studies, its concentration is often estimated indirectly from measures of total testosterone and SHBG. Moreover, the statistical power of some studies is often limited by small sample size, by the observation of relatively small differences (usually 10-15%) between cases and controls, or by fairly large intra-and inter-assay laboratory variations in circulating hormone assays (38) . In addition, it is unclear whether circulating levels of androgens reflect the androgenic environment within the prostate, since DHT in the prostate gland mainly comes from intra-prostatic conversion of testosterone. Also unclear is whether cumulative exposure to androgens over a lifetime or exposure at certain points in life is more relevant in prostate carcinogenesis. Hormonal changes during the prenatal and peri-pubertal period may be of etiologic importance, because prostate development, including substantial epithelial cell differentiation, occurs at these critical time periods (39) . Accordingly, if early exposure to androgens is most critical for the development of prostate cancer, then most epidemiologic studies that measure circulating hormone levels of hormones in study subjects who are typically in their sixth decade of life would miss the etiologically relevant period of exposure. Thus very long-term studies may be needed to examine this hypothesis. Lastly, the heterogeneity of prostate cancer may influence results, as evidenced by the different findings observed for serum testosterone by tumor aggressiveness (30) . Future studies will need to address this by stratifying by disease grade and/or stage.
A better understanding of the hormonal milieu within the prostate gland and its relationship to circulating hormones would be critical to interpret results from serumbased studies. However, epidemiologic studies of tissue androgen levels are impeded by various methodologic problems associated with prostate tissue collection and methods for tissue hormone measurements. These problems are compounded by the lack of a normal comparison group for analytic studies, since ethical considerations often preclude the collection of "normal" tissue from healthy subjects. In addition, the high prevalence of latent prostate tumors in elderly men means that identification of age-matched controls with no histological evidence of prostate cancer is very difficult.
Androgen-Related Genes
Because prostate cancer is an androgen-mediated tumor, it is likely that markers in genes whose products are involved in androgen biosynthesis and metabolism are involved in prostate cancer etiology. Ross et al. (40) first proposed a polygenic model to help explain the racial/ethnic difference in prostate cancer risk. That model triggered a series of studies that investigated the involvement of genes encoding cytochrome P450 17alpha-hydroxylase (CYP17), aromatase (CYP19), steroid 5alpha-reductase (SRD5A2), 3beta-hydroxysteroid dehydrogenase (HSD3B2), and androgen receptor (AR) in prostate cancer. These candidate genes and several others are discussed in this review, and are summarized in Table  1 . Although these data are promising and accumulating at a remarkable pace, they are still too sparse to support a definitive role for any particular gene.
AR and AR Coactivators
Possibly the most-studied gene with regard to prostate cancer is that encoding the AR. The AR is expressed in all histological types and stages of prostate cancer (41) . Numerous somatic mutations in the AR gene, located on the long arm of the X chromosome, have been reported among prostate cancer patients enrolled in clinical studies. Most of these mutations have been detected in tumor tissue of late stage prostate carcinoma, with consistent findings showing that somatic mutation of the AR gene is involved in the progression and aggressiveness of prostate cancer (41) . Most epidemiologic studies of the AR gene have focused on two trinucleotide repeat polymorphisms in exon 1, the (CAG) n and (GGN) n where N stands for any nucleotide) repeats, which encode polyglutamine and polyglycine, respectively. The (CAG) n repeat length ranges from 11 to 31 repeats in most men, and experimental data show that shorter (CAG) n repeat lengths are linked to increased AR trans-activation activity (42, 43) . In addition, (CAG) n repeat length has been linked to male pattern baldness (44, 45) , a clinical condition associated with higher DHT levels and prostate cancer risk. Epidemiologic studies show, that in general, shorter (CAG) n repeat lengths are associated with increased risk in many but not all populations . Evidence of association for the second repeat, (GGN) n , is less consistent than that for (CAG) n , and the story is complicated by variations in the way in which the numbers of repeats were counted in the various studies: some counted only (GGC) n , while others counted any (GGN) n . However, a recent meta-analysis reports that AR (CAG) n or (GGN) n repeat length is unlikely to have a major biological role in prostate cancer because the pooled effect size is not large, and the absolute difference in number of (CAG) n or (GGN) n repeats between cases and controls is less than one (74) Two other polymorphisms in the AR gene have been investigated for their associations with prostate cancer. The first is the R726L mutation in the hormone binding region of exon E, which despite a reported 6-fold increase in risk, has been observed only in Finnish men (75, 76) .
This marker is in strong linkage disequilibrium (LD) with the (CAG)n repeat marker, such that those with the variant allele invariably have 26 (CAG)n repeats. The second polymorphism is StuI, also designated E211G/A, which is a synonymous polymorphism located on exon 1 between the (CAG)n and (GGN)n repeats and is in linkage disequilibrium with both. This marker has been linked to prostate cancer risk in African-Americans and in Brazilians (40, 77) , but not Australians (71) . The observed associations of the R726L and the StuI markers with prostate cancer are likely to be influenced by their linkage with the trinucleotide repeats, and the synonymous nature of the StuI marker strongly suggests that this marker's association is unlikely to be causal.
AR coactivators enhance transactivation of the AR several fold (24) and therefore potentially increase the risk of prostate cancer. One AR co-activator, encoded by the AIB1 (Amplified in Breast Cancer 1) gene located in chromosome band Xq11-12, has a (CAG)n/(CAA)n (polyglutamine) trinucleotide repeat. Two epidemiologic studies have investigated the role of this repeat polymorphism in prostate cancer: one found a positive association between AIB1 (CAG)n repeat length and prostate cancer (78) , and the other reported no association (79) . Because of their importance in modulating the effects of androgenic action, future studies should be directed at clarifying the combined effects of AR and AR coactivators in prostate cancer risk.
CYP17
Cytochrome P450c17alpha hydroxylase, encoded by the CYP17 gene located in chromosome band 10q24.3, catalyzes critical steps in the biosynthesis of testosterone. A single base pair change (T to C) in the 5'-untranslated region (UTR) of the CYP17 gene (C nucleotide, or A2 allele), has been linked to male pattern baldness (80), a putative risk factor for prostate cancer. Interestingly, the A2 allele of this CYP17 marker is also associated with higher levels of serum estrone and an increased risk of breast cancer compared to the A1 allele (81) . However, the relationship between CYP17 and prostate cancer is inconclusive. Of the 16 epidemiologic studies that have examined the role of CYP17 in prostate cancer (57, 65, 68, 70, (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) , 4 found a positive association with the A2 allele (82, 84, 87, 88) , while 4 others found elevated risk associated with the A1 allele (83, 85, 91, 93) . Nevertheless, a recent meta-analysis concluded that evidence to date provides no evidence of overall association of the CYP17 gene with prostate cancer (94) . In addition, two epidemiologic studies with data on circulating levels of hormones found no association between the CYP17 marker and serum levels of either testosterone or 3alpha-diol G (86, 95) . These results suggest that the effect of CYP17 on prostate cancer, if any, is likely to be small. 
CYP19
The CYP19 gene, located in chromosome band 15q21.1, codes for the key steroidogenic enzyme aromatase, which catalyzes the irreversible conversion of androstenedione to estrone and testosterone to estradiol. Aromatase is present in the gonads and in the extragonadal organs and tissue, including the prostate and adipose tissue. In men, conversion of androgen to estrogen occurs mostly in the adipose tissue. To date, five studies have investigated the role of CYP19 polymorphisms in prostate cancer (57, 58, (96) (97) (98) . Two out of three studies report a positive association with the tetra-nucleotide repeat (TTTA) n in intron 4 (57, 96) ; however, the categorization of alleles and genotypes for this marker are inconsistent, and comparisons between studies are therefore difficult to make. Another study reported that the variant allele of the Arg264Cys polymorphism in exon 7 (a C to T substitution) (58) was associated with a 72% non-significant increased risk of prostate cancer, a finding which was not confirmed in a subsequent investigation (97).
SRD5A2
Cross-sectional surveys show that western men have higher serum levels of 3alpha-diol G than native Japanese men (99) and higher chest hair density than Chinese men (100). Because serum levels of 3alpha-diol G and body hair reflect steroid 5alpha-reductase activity, these observations led to the hypothesis that population differences in steroid 5alpha-reductase activity and/or the polymorphisms of the SRD5A2 gene, which encodes the type 2 steroid 5alpha-reductase enzyme, may be related to the development of prostate cancer and may contribute to part of the large racial/ethnic differences in risk (40) .
More than 22 mutations, including 10 single amino acid missense substitutions, have been reported for SRD5A2 (101) . Four of these mutations --A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA) n dinucleotide repeat --have been investigated for their association with prostate cancer in eighteen epidemiologic studies that have produced mixed results (Table 1) (57, 65, 68, 70, 82, 87, (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) (113) . Of the 11 studies investigating the A49T marker in the SRD5A2 gene which increases enzyme activity 5-fold in vitro (101) , just one reported a statistically significant association between the T variant and prostate cancer, and this association was only significant among U.S. Blacks (104) . However, a case series reported that the A49T genotype was associated with more aggressive prostate cancer (114) . In general, the results of the studies investigating the prostate cancer associations of the V89L marker (57, 65, 68, 70, 82, 87, 103, 105, 106, (108) (109) (110) (111) (112) (113) , which modestly reduces enzyme activity in vitro and in vivo (101) and the (TA) n repeat length marker (57, 70, 102, 105, 108, 111) , which has no known functional relevance are mixed. It is interesting to note that relative to Western men, Asian men have a higher prevalence of V89L marker's LL genotype, which is associated with lower serum levels of 3alpha-diol G (101). The R227Q mutation, which is related to male pseudohermaphroditism and almost abolishes enzyme activity (101), has been detected only in Asians, and the only study investigating its role found no significant association with prostate cancer risk (108) .
The inconsistent findings in the SRD5A2 markers in various studies are largely due to the low frequency of certain mutant alleles of some markers in the SRD5A2 gene. For example, other than the V89L mutation, the frequency of the mutant alleles in various markers (including A49T and R227Q) is less than 5%, limiting the power of detection. Nevertheless, in a recent metaanalysis, Ntais et al. concluded that overall, the T allele of the A49T marker is associated with a modest risk increase, and although evidence is less consistent, the LL genotype of the V89L marker and longer (TA) n repeats may be associated with increased risk as well (115).
HSD3B and HSD17B
Incomplete activation or slow catabolism of DHT within the prostate can lead to the accumulation of DHT and, perhaps, increased androgenic action. Thus, enzymes that catalyze the break down DHT may be of etiologic importance for prostate cancer. As shown in Figure 2 , at least four enzymes, 17beta-hydroxysteroid dehydrogenase type I (encoded by the HSD17B1 gene), 17beta-hydroxysteroid dehydrogenase type III (encoded by the HSD17B3 gene), 3alpha-hydroxysteroid dehydrogenase (encoded by the HSD3A gene), and the 3beta-hydroxysteroid dehydrogenases (encoded by the HSD3B1 and HSD3B2 genes located at 1p13 and 1p13.1), are involved in the metabolism of DHT within the prostate. Three studies have examined these genes. One reported a significant association of the G289S polymorphism in the HSD17B3 gene (116) and another reported an association of the N367T marker within the HSD3B1 gene, but no prostate cancer associations of the c7062t marker in HSD3B1 and the c7159g and c7474t SNPs in HSD3B2 (117) . These early results are evidence for a role of these genes in prostate cancer risk, but further studies are needed. In contrast, the most recent study, a comprehensive examination of the HSD17B1 gene, examined cases and controls from a consortium of cohort studies (118) . Through a combination of large sample size (>8000 cases and >9000 controls), multiple ethnicities, and utilization of haplotype-tagging SNPs rather than single SNPs, overall this study lays out strong evidence for a lack of association of the HSD17B1 gene with risk.
CYP3A4
The CYP3A (cytochrome P450, family 3, subfamily A) subfamily members CYP3A4 and CYP3A5 are located at a single locus on chromosome 7q21-q22. The CYP3A4 gene product is involved in oxidative conversion of testosterone to the biologically less active forms 2beta-, 6beta-, and 15beta-hydroxytestosterone, and the variant *1B allele of the A-391G SNP in the 5'-upstream region has been linked to higher prostate cancer stage and grade (119) .
Furthermore, the striking differences in *1B frequencies between Caucasian populations and populations of African extraction (120) suggest that this SNP may be related to racial differences in prostate cancer risk. However, while one case-control study showed significant excess risk of aggressive disease with the *1B allele among African-Americans, it did not find this risk among Caucasians (121) . Other studies showed a modest but non-significant reduced risk of prostate cancer in connection with the variant *1B allele (65, 122, 123) . The low frequency of the variant in most populations limited the statistical power of many of these studies.
CYP3A5
The CYP3A5 gene product, highly expressed in the prostate, is a major contributor to the metabolic clearance of many CYP3A substrates, including drugs and other xenobiotic compounds, as well steroid hormones. A number of polymorphic markers have been identified in the CYP3A5 gene, two of which have been studied in epidemiologic studies of prostate cancer. The CYP3A5*1 marker, whose variant allele may promote inactivation of testosterone (124) , was found to have a borderline significant association with reduced risk of prostate cancer in one study (122) but not another (123) . The variant allele of a different marker, CYP3A5*3, results in a truncated and presumably less functional protein (125) , supporting the observation in a Japanese population that the CYP3A5*3 wild-type allele was associated with reduced prostate cancer risk (124).
ESTROGENS AND ESTROGEN RECEPTORS
Estrogens in Prostate Cancer
The prostate obtains estrogens from peripheral sources (such as adipose tissue) and through stromal conversion of testosterone. Although estrogens are used as anti-androgens in the treatment of prostate cancer, their etiologic role is unclear. Several lines of evidence suggest that estrogens may enhance prostate carcinogenesis. Estrogens interact with SHBG and androgen to regulate normal prostate growth and function (126) , and mediate epithelial cell responses to androgens via the IGF pathway (127) . Induction of prostate tumors in laboratory rats by testosterone administration is considerably enhanced by the addition of estradiol (128) . In addition, prenatal exposure to extremely low doses of diethylstilbestrol (DES) and other estrogenic compounds in the presence of androgen significantly affects rodent prostate development in vivo and in vitro (129) , leading to imprinting and increased estrogen sensitivity later in life (5) . Finally offspring of DES-exposed mothers have an elevated risk of prostate cancer (130) .
Together, these data suggest that estrogens may increase the risk of prostate cancer. While Gann et al. (16) found that higher levels of serum estradiol were associated with a reduced risk of prostate cancer, it is unclear whether physiologic or pharmacologic estrogen doses were used in this study. It is possible that at physiologic doses, estrogens have anti-tumor effects via the hypothalamicpituitary-gonadal axis, while at pharmacologic levels, estrogens work alone or in conjunction with androgens to promote tumor growth.
Estrogen Receptors in Prostate Cancer
Estrogen receptors (ERs) mediate the biologic effect of estrogen in target tissue (131) . It has been suggested that the concentrations of the two distinct ERs, ER-alpha and ER-beta, may affect prostate cancer risk through the influence of the estrogen-ER complex on AR concentration (132, 133) . Although most molecular studies show evidence of ER-alpha expression in prostate stromal cells, ER-alpha is not considered to be highly expressed in prostate carcinoma. On the other hand, the more recently discovered ER-beta is highly expressed in prostatic epithelium (131) . In addition, ER-beta may be involved in the regulation of AR content in the prostate and in epithelial growth, and may thus serve as a physiologic regulator of prostatic epithelial growth and differentiation (134). The role of estrogens in prostate carcinogenesis is still unclear; however evidence is mounting that this role may be a fertile area for additional research.
Estrogen-Related Genes
Estrogen receptor-alpha, coded by the ESR1 gene, has been examined in two studies (58, 97) , both of which showed no association of the ESR1 XbaI and PvuII restriction fragment length polymorphism (RFLP) markers. However, the first study did observe significant 3-to 5-fold excess risks among subgroups defined by both the ESR1 markers and AR repeat lengths. Just one study has examined the risk of prostate cancer associated with ERbeta, encoded by the ESR2 gene, and found no significant association of the RsaI RFLP marker (97).
SEX HORMONE-BINDING GLOBULIN (SHBG)
Role of SHBG in Sex Hormone Transport
Sex hormone-binding globulin (SHBG) transports androgens and estrogens in the circulation. In the only study to report a definitive positive association between serum levels of testosterone and prostate cancer, Gann et al. (16) found no statistically significant association between prostate cancer risk and testosterone before controlling for serum levels of SHBG. After adjusting for androgen and estradiol, Gann et al. found that serum levels of SHBG were associated with a 54% reduced risk of prostate cancer (16) . Although it is not entirely clear whether adjustment for SHBG is the best approach to assess the independent effect of testosterone, the Gann et al. study showed that the effect of serum testosterone was more pronounced after adjustment for SHBG.
Role of SHBG in Prostate Cancer
Recent data suggest that SHBG may have an effect on carcinogenesis that is independent of its function as a regulator of the free fraction of androgen and estrogen. For example, SHBG mediates steroid hormone signal transduction at the plasma membrane, thereby allowing certain steroid hormones to act without entering the cell by interacting with SHBG membrane receptors (135) . In addition, estradiol can activate the AR by using SHBG as an intermediate (136). However, this pathway is complex and not well understood, and the potential independent effects of SHBG have not been investigated fully.
Because several factors, including estrogens, androgens, thyroid hormones, insulin, leptin, and IGF1 affect circulating levels of SHBG (137) (138) (139) (140) , future studies should measure SHBG along with several other hormones and evaluate its independent effect on prostate cancer risk.
INSULIN AND LEPTIN
Circulating Insulin and Leptin Levels and Prostate Cancer
Serum levels of insulin and leptin are associated with obesity and body fat distribution, two putative risk factors for prostate cancer (141, 142) . The roles of insulin and leptin in prostate carcinogenesis have been investigated in three casecontrol studies (143) (144) (145) . Two of these studies, both casecontrol investigations, reported no association of serum leptin with prostate cancer risk (143, 144) , while the nested casecontrol study from Sweden found a positive association (145) . In addition, a recent clinical survey (146) showed that higher plasma levels of leptin were associated with larger (>0.5 cm3) prostate tumor volumes. Furthermore, one of the two case-control studies also reported a positive association with serum levels of insulin (144) . This association was independent of overall and abdominal obesity as well as serum levels of IGFs, sex hormones, and leptin. Serum levels of C-peptide, a marker of insulin secretion from pancreatic beta cells, were found to be associated with aggressive prostate cancer in a recent prospective study (147).
Insulin's primary mode of stimulating cell growth is through binding to the insulin receptor and activating a cascade of post-receptor events involved in cell survival and proliferation (148) (149) (150) . Insulin may also affect prostate tumorigenesis through several other potential pathways, including the obesity-sex-hormone pathway, the IGF pathway, the PI3-kinase (phosphatidylinositol 3'-kinase) signaling pathway, and the apoptotic pathway. In the obesity-sexhormone pathway, insulin increases the transcription of CYP17 (the gene encoding the enzyme critical to the biosynthesis of testosterone) and decreases the synthesis of SHBG (151, 152) , thereby increasing the bioavailability of free testosterone for uptake by the prostate gland. In addition, insulin can regulate aromatase activity, thus influencing the conversion of androgens to estrogens (153, 154) . Because of the high degree of homology between insulin and IGF (50% amino acid homology and 60% receptor homology), insulin can bind to the type I IGF receptor and initiate IGF-mediated growth (155) . Insulin can also inhibit transcription of IGF binding protein 1, thereby increasing unbound circulating IGF1 (155) . In recent studies, higher circulating levels of IGF1 have been linked to an increased risk of prostate cancer (156) . Although epidemiologic evidence for the association between insulin and prostate cancer is preliminary, the roles of insulin and leptin need to be clarified further because they may help explain the strong differences in prostate cancer incidence across populations.
Insulin and Leptin Genes
To date, four studies have examined variants of the insulin gene with risk of prostate cancer, and all have been conducted in U.S. subjects. (157) (158) (159) (160) . Two of these four studies (157, 158) show excess risk associated with the CC genotype of the PstI marker in the INS gene, which encodes insulin. In addition, one of the two studies that have examined the role of insulin receptor substrate (IRS)1 (159, 160) shows an association with the IRS1 G972R marker (159) , while the single study examining IRS2 shows no prostate cancer risk associated with the G1079D marker (159) . The only study of the leptin gene LEP showed a strong association with prostate cancer risk in Portuguese Whites, an effect that was even more pronounced for advanced stage disease (161) . However, the only study of the leptin receptor gene LEPR showed no association of two markers with early onset prostate cancer in the United Kingdom (162) . Genetic studies of the association of the insulin and leptin axis with prostate cancer are still in the early phases, and evidence will continue to accumulate.
INSULIN-LIKE GROWTH FACTOR (IGF) AXIS
IGF Axis and Prostate Cancer
IGF1 and IGF2 are polypeptides that function as both tissue growth factors and endocrine hormones, with strong mitogenic and anti-apoptotic effects on prostate epithelial cells. The six known IGF binding proteins (IGFBPs) are able to bind to IGFs, thus preventing the activation of IGF receptors. Over a dozen studies, both retrospective and prospective, have examined the role of circulating elements of the IGF axis in prostate cancer. Overall, the evidence suggests that higher IGF1 levels are associated with increased risk of prostate cancer (156, (163) (164) (165) (166) (167) , and that this association is strongest for advanced disease (163, 165, 166) . In contrast, although the evidence is not as consistent, increasing levels of IGFBP3, and possibly IGFBP1, appear to be associated with decreased prostate cancer risk (163, 168) . The evidence for involvement of the IGF axis in prostate cancer is compelling, and should be a fruitful area for future research.
IGF Axis Genes
The genes encoding IGF1, IGF2, and IGFBP3 have been studied with regard to prostate cancer risk. A CA tandem repeat polymorphism in the IGF1 gene has been linked to prostate cancer risk in most (65, 169-171), but not all published studies (159, 172) . In contrast, the studies of the IGF2 MspI marker (157) and the IGF2 ApaI marker (173) , as well as all studies of markers in the IGFBP3 gene (65, 169, 170, 172, 174) have been null. Investigation of IGF-related genetic markers in prostate cancer risk is still in its early phases, and data are still accumulating.
VITAMIN D
Vitamin D and Prostate Cancer
Vitamin D is a steroid hormone synthesized primarily in skin in response to sunlight exposure. Vitamin D and its analogs have potent anti-proliferative, prodifferentiative, and pro-apoptotic effects on prostate cancer cells in vitro (175) , and vitamin D inhibits prostate tumor growth in vivo (176) . A clinical trial of calcitriol, the most biologically active ligand for the vitamin D receptor (VDR), is currently underway to investigate additive antineoplastic activity with docetaxel in men with advanced hormone refractory prostate cancer (177) .
However, despite the strong and consistent laboratory evidence linking vitamin D to prostate cancer, five prospective studies investigating serum levels of vitamin D and prostate cancer risk have produced inconsistent results (6).
Vitamin D Receptor (VDR) Gene
The strong laboratory evidence linking vitamin D to prostate cancer paved the way for a number of epidemiologic studies of the VDR gene, the primary mediator of vitamin D's physiologic action. However, despite promising early results, 21 studies of the 3' poly-A, TaqI, BsmI, and ApaI polymorphic markers, as well as the functional 5' FokI marker, in a variety of populations show mixed results (46, 65, 70, (178) (179) (180) (181) (182) (183) (184) (185) (186) (187) (188) (189) (190) (191) (192) (193) (194) (195) (196) . A recent metaanalysis (197) concludes that there is no evidence of association of the VDR gene with prostate cancer.
GONADOTROPINS
Gonadotropins, including luteinizing hormone (LH), follicle-stimulating hormone, and prolactin, are secreted by the pituitary and are involved in feedback control of testosterone, and gonadotropin-releasing hormone agonists are used to treat prostate cancer. Gonadotropins are not routinely measured in epidemiologic studies because their levels are influenced by pulsatile secretion and diurnal variation, which complicate their measurement and thus the assessment of their roles in prostate cancer. Data from one study has suggested that higher serum levels of LH, in concert with testosterone, may be associated with an increased risk of prostate cancer risk (29). Prolactin mediates the entry of testosterone into prostatic cells in vitro and in vivo (198) . However, there are not many epidemiologic studies examining the role of circulating prolactin in prostate cancer (16, 29, 37, 199) . The biological relevance of gonadotropins to testosterone suggests that their roles in prostate cancer need to be clarified in future studies.
FUTURE DIRECTIONS
Prostate cancer is a complex, multi-factorial disease with a well-recognized heritable component. Hormones, particularly androgens, clearly play a role in prostate carcinogenesis.
However, despite a great deal of investigation using a variety of approaches, this role is not yet completely clear, due to a number of shortcomings. The following section describes how these shortcomings can be addressed in the future.
Studies of Hormones in Prostate Tissue
It is as yet unclear how circulating hormone levels relate to intra-prostatic levels, and whether intraprostatic metabolism is more relevant to the etiology of prostate cancer than serologic measurements. To shed light on this, methodological studies should be carried out to collect high quality normal prostate tissue specimens for the measurement of tissue hormones, enzymatic activities, and receptor proteins. For androgens, this could result in the derivation of an overall serological index of intraprostatic androgenicity. In addition, validated tissue hormone assays can be used to assess whether smoking, alcohol use, body size, and other lifestyle factors affect tissue levels of hormones. Racial or ethnic differences in tissue levels of hormones should also be evaluated after taking into account lifestyle and other potential confounding factors. It would also be useful to correlate tissue levels of hormones with genetic variants to provide insights into the functional significance of these polymorphic markers. To do so, peripheral lymphocytes or buccal cells should also be collected from study participants so that DNA may be extracted and genotyped for relevant polymorphisms in hormone-metabolizing genes.
Studies of Hormones in Circulation
Because it is often infeasible to measure tissue hormone levels in observational epidemiological studies, future studies, particularly nested case-control studies, will continue to rely on serum-based assays of hormone levels. Clearly, in case-control studies, careful measures should be taken to minimize variation in assays and blood sampling. These measures should include the use of sensitive and specific assays to minimize measurement error, as well as simultaneous measurement of several hormones in the same study to provide a more complete hormonal profile of each study subject so that the net effect of each hormone can be assessed.
For example, liquid or gas chromatography-mass spectroscopy (GC-MS) assay methods can be used to derive a complete profile of androgen and estrogen metabolites, which may help provide insight into whether other androgen metabolites more accurately reflect tissue levels of androgens, leading to more reliable and accurate assessment of the relationships between sex steroids and prostate cancer. Furthermore, blood collection times should be standardized so that diurnal and seasonal variation in hormone levels among study subjects can be minimized, and investigators should use large enough sample sizes (preferably several hundred case-control pairs from prospective studies) to yield sufficient statistical power.
Analytically, it is important to stratify results by stage and/or grade, as risk factors for more aggressive disease may differ from those of less-aggressive disease. In addition, it is important to have a better understanding of factors that affect circulating levels of hormones so that appropriate statistical analyses can be conducted to control for confounding. For example, methodological studies examining relationships between epidemiologic factors, such as anthropometry, physical activity, or diet, and the interrelationships among hormones, including androgens, estrogens, IGFs, SHBG, leptin, and insulin, should be carried out to provide critical data to help refine the analytical models in the statistical analyses. In addition, one of the concerns of retrospective studies is that hormone measurements may be influenced by disease. To address this, results from retrospective studies should be interpreted only in the context of supportive prospective data. Because the validity of the results hinges on the quality of hormone assays, we cannot stress enough the importance of optimizing hormone measurements in future studies. Imperfect as they may be, serum levels of hormones, if measured accurately, presumably reflect the combined effects of studied genetic polymorphisms as well as effects of other genes and exogenous factors, and can provide valuable clues to the role of hormones in prostate cancer risk.
A better understanding of how serum hormone levels vary in different racial and ethnic populations at varying prostate cancer risk may shed light on the etiology of prostate cancer. In addition, studies that measure the levels of circulating hormones in various decades of life may help identify critical time periods in life that are etiologically relevant to prostate cancer risk. Because levels of circulating testosterone in pregnant black women are higher than those in pregnant white women, it has been suggested that in utero exposure to testosterone may explain the excess prostate cancer risk in African American men (200) . Comparisons of hormone levels in cord blood from various racial/ethnic groups may provide additional insights into this hypothesis.
These suggested methodological studies, although cross-sectional in nature, should be guided by sound epidemiologic principles and include probability samples from each population in order to aid in the interpretation of results.
Studies of Genes
The characterization of hormone metabolizing genes provides an opportunity to examine disease at the level of germline susceptibility. Compared to serum-based studies, this approach has two distinct advantages. First, genetic assays usually, but not always, produce more qualitative (categorical) results with higher reproducibility than the continuous data typically produced by serologic assays. Second, unlike serologic markers in cross-sectional case-control studies, genetic susceptibility status (i.e., genotype) is not affected by the presence or process of disease or by other exposures that may change over time. Despite these advantages, there are serious limitations to studies of genetic polymorphisms and prostate cancer risk.
Incomplete gene coverage is a major problem in many studies. Most studies of genetic associations to date have focused on a small number of variants and candidate genes, often genes that are related to one another or in a common pathway. In an attempt to assess the overall association of these genes with prostate cancer, study subjects are typically genotyped for 5-10 candidate polymorphisms within these genes.
However, the polymorphisms known to exist within the gene often number in the hundreds or thousands. Thus, most studies to date have assessed but a small fraction of the genetic variation within a given gene. Accordingly, observed associations may in fact be due to linkage with a true causal marker elsewhere in the region. Functional data on a marker can help improve the interpretation of such results, but they are rarely available. In addition to these concerns about false positive results for individual markers, it is important to note that failure to observe an association of studied markers when gene coverage is incomplete can also lead to falsely concluding that the studied gene is not associated with disease (false negatives). To address these concerns, studies are now incorporating more SNPs into their genetic panels.
In addition, studies are taking advantage of recent advances in identification of haplotype tagging SNPs and haplotype estimation techniques that have improved our ability to study the influence of genes on disease risk knowing that some fixed percentage of the gene's diversity is being assessed, while concomitantly minimizing the number of SNPs that must be typed. Data from the Human Genome Project and the International HapMap Project (www.hapmap.org) have become useful in this aspect, and when paired with recent advances in informatics tools, these may permit a more comprehensive interrogation of genetic loci of interest. Functional considerations, however, also should be kept in mind.
Multiple comparisons is also a serious and growing issue in genetic epidemiology studies, due in large part to recent advances in technology that enable rapid collection of vast amounts of genotyping data. For example, many studies now routinely examine 20 or more SNPs in each of perhaps 5-10 genes, resulting in over 100-200 individual comparisons in a single analysis. By chance alone, 5-10 of these comparisons are likely to be positive. Thus, without pre-specified hypotheses, many observed findings are likely to be false positive results. This is especially true for common, low penetrance markers, as these are unlikely to have strong true risk estimates. Although statistical corrections including Bonferroni and Sidak tests, or Bayesian approaches such as the False Positive Report Probability (201) have been employed in some studies, the issue of false positives remains a major one in the literature.
Despite the concerns about false positives and false negatives, studies of individual markers within genes continue to be an important source of new leads for prostate cancer etiology research, particularly for new hypotheses involving the interplay of genetic and environmental factors. Statistical approaches to addressing false positives aside, replication of findings in studies involving different designs and populations is the most compelling evidence that an association is real. It should be noted that replication is necessary not only for positive results, but for null results as well.
Lack of sufficient statistical power is another concern. Most current studies have limited power to detect effects of rare (<5%) alleles, due to relatively small numbers of subjects (usually fewer than 500). Furthermore, even if a study has satisfactory power to examine the main effects of a single genetic locus, it rarely has sufficient power to evaluate the combined effect of several genes, or of genes with other exposures. Thus, most individual studies cannot produce a comprehensive picture of genetic predisposition and cancer risk.
Due to the large number of often mixed studies, an important need in the field is a high-quality synthesis of the literature. For prostate cancer, there are a number of rigorously conducted meta-analyses, as shown in Table 1 . Such reviews can be extremely helpful in examining the totality of available evidence for a given locus. However, unpublished work, which often tends to show null results, is difficult to include in such syntheses. One answer to this is the formation of consortia of existing studies (202) . Not only can these groups improve the field by planning at the outset to replicate results, positive or null, from one participating study, but they can conduct pooled analyses of individual-level data, thereby improving upon the studylevel summaries of most meta-analyses. Such consortia have been formed in other areas, most notably nonHodgkins lymphoma (203) .
In addition, risk estimates can be influenced by latent ancestral differences between cases and controls that may confound the observed association, often called population stratification (204) . While there is debate on the magnitude of the impact of population stratification on disease associations, methods for addressing population stratification are available, including the recently proposed use of ancestry informative genetic markers, wherein the ancestral background of each individual is assessed using a validated panel of markers and incorporated into regression modeling (205) . Family based association studies are also useful in guarding against population stratification, but due to the late onset of prostate cancer (indeed, of most cancers of any site) the use of designs that require participation and genotyping of parents and/or siblings is impractical.
Prostate cancer is a complex disease likely involving interplay of multiple risk factors, thus it is unlikely that a single common polymorphism will have a profound effect on androgen levels or prostate cancer risk. Instead, alterations in multiple susceptibility genes may be required to heighten prostate cancer risk. Many of the studies to date have examined a single aspect of hormone pathways, as opposed to an integrated examination of the interplay of several factors simultaneously. Recent advances in bioinformatics and statistical techniques, including pathway-based SNP selection strategies implemented in GenMAPP (Gene Map Annotator and Pathway Profiler (206), as well as hierarchical regression modeling (207) and multifactor dimensionality reduction (208) may help in clarifying the joint effects of multiple genetic and hormonal risk factors in prostate cancer risk.
An emerging trend in epidemiology studies is the use of whole genome approaches to scan hundreds of thousands of SNPs in large numbers of cases and controls to identify disease genes in the absence of a specific hypothesis. Multiple testing issues abound here, but through adoption of sequential marker screening strategies, and with sufficient samples sizes, such approaches may capture major variants that are highly related to endpoint of interest, such as prostate cancer. A good example of this is the NCI Cancer Genetic Markers of Susceptibility Study (http://cgems.nci.nih.gov/), which plans to scan more than 550,000 SNPs in prostate cancer cases and controls from at least five independent studies. The initial scan of 550,000 SNPs will be conducted on 1,200 cases and 1,200 controls, and is expected to show an estimated 20,000 SNPs with positive associations at p<0.05. These SNPs will then be confirmed in independent sub-samples of the sample set, and the approximately 25-30 SNPs that are consistently related to prostate cancer in all studies will undergo extensive investigation, including sequencing and functional studies, to provide further insight for prostate cancer etiology. This approach is expensive but is likely to provide credible evidence on a number of major loci with robust association with prostate cancer risk in several populations as a result of the replication process.
An effective means of addressing several of the shortcomings noted above is to explore hormones and hormone-related loci in large (several thousand cases) prospective studies with high-quality biological specimens and exposure assessments. We suggest that a large set of common polymorphisms of susceptibility genes involved in hormone pathways be assessed simultaneously in such studies. Furthermore, since prostate cancer is likely to result from a complex interplay of genetic and environmental factors (209) and since the expression of genetic traits is likely to be influenced by exogenous factors, investigation of interactions between genes and environmental/lifestyle factors should be conducted in large study populations with sufficient statistical power. One good example of such a large study is the Prostate Cancer Cohort Consortium (http://epi.grants.cancer.gov/BPC3/), a collaboration of dozens of large, prospective cohorts, which to date has assembled over 9,000 cases of prostate cancer for joint study and plans to utilize a candidate gene approach (210) . Results from the combined analysis of these cohorts will help clarify the role of hormones in prostate cancer risk, and provide a more complete view of genetic predisposition to prostate cancer and identify susceptible subgroups for early detection.
SUMMARY
In summary, although many pieces of the puzzle in our understanding of the role played by hormones in prostate cancer are still missing, promising clues are emerging. A wealth of new data, including hormone levels in various biological samples, combined with an exciting new array of genetic information, is becoming available and may soon reveal more specific exposure-disease relationships that will enhance our understanding of hormonal carcinogenesis in prostate cancer. Such efforts, however, require a concerted interdisciplinary approach that combines the efforts of investigators across several disciplines, including epidemiology, urology, pathology, biochemistry, endocrinology, genetics, and molecular biology. In addition, it requires large epidemiologic study populations, such as those being achieved now by large consortia. Such studies will provide unique opportunities to incorporate state-of-the-art techniques to test emerging hypotheses in a timely fashion.
